Q1 earnings take off, Lilly strikes deals, Regeneron notches historic approval, FDA raises questions
First quarter earnings are coming in at a rapid pace, with Sanofi and Novartis defending patents for Dupixent and Lutathera, respectively, and Sanofi welcoming Belén Garijo as CEO. Still to come this week are Eli Lilly, AstraZeneca, Regeneron and many more.
Lilly will undoubtedly discuss its recent streak of dealmaking, including a $2.25 billion pact with AI biotech Profluent, plus buyouts of Ajax Therapeutics for up to $2.3 billion and Kelonia Therapeutics for up to $7 billion.
Meanwhile, Regeneron earned FDA approval for the highly anticipated gene therapy that will now be known as…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.